Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL). (17th October 2013)

Record Type:: Journal Article
Title:: Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL). (17th October 2013)
Main Title:: Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)
Authors:: Hill, Brian T.
Caimi, Paolo
Kindwall‐Keller, Tammy
Habecker, Becky
Kalaycio, Matt
Abstract:
Is Part Of:: British journal of haematology. Volume 164:Number 2(2014:Jan.)
Journal:: British journal of haematology
Issue:: Volume 164:Number 2(2014:Jan.)
Issue Display:: Volume 164, Issue 2 (2014)
Year:: 2014
Volume:: 164
Issue:: 2
Issue Sort Value:: 2014-0164-0002-0000
Page Start:: 297
Page End:: 299
Publication Date:: 2013-10-17
Subjects:: Hematology -- Periodicals
Blood -- Diseases -- Periodicals
616.15
Journal URLs:: http://www.blacksci.co.uk/%7Ecgilib/jnlpage.bin?Journal=bjh&File=bjh&Page=aims ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2141 ↗
http://onlinelibrary.wiley.com/ ↗
DOI:: 10.1111/bjh.12604 ↗
Languages:: English
ISSNs:: 0007-1048
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 2309.000000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 3747.xml